Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (NASDAQ:RCEL) will host an investor webinar on May 20, 2026 at 4:00 p.m. PT (May 21, 2026 at 9:00 a.m. AEST), featuring President and CEO Cary Vance and CFO David O’Toole. The event will review recent Q1 2026 earnings results and include a Q&A session.
The company will also hold an in-person armchair investor discussion in Melbourne on May 21, 2026 at 4:00 p.m. AEST, covering its acute wound care platform, portfolio, commercial progress, and 2026 execution priorities. Replays of both events will be available on AVITA Medical’s investor relations website.
AVITA Medical (NASDAQ: RCEL) reported Q1 2026 revenue of approximately $19.3 million, up 4% year-over-year and ~10% sequentially, with gross margin of 81.7% and operating expenses down 11% to $24.5 million.
Net loss improved to $10.6 million ($0.35/share). The company reaffirmed 2026 revenue guidance of $80–$85 million, entered a 10-year BARDA agreement worth up to $25.5 million, announced positive interim Cohealyx data, and received RECELL GO clearance in Australia and New Zealand. Leadership changes include Cary Vance as CEO and Jan Stern Reed as Board Chair.
AVITA Medical (NASDAQ: RCEL) appointed Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. The Board also named Jan Stern Reed as Chair, effective immediately. Mr. Vance will remain on the Board as an executive member.
The Board described a thorough search and credited Vance with stabilizing the business, sharpening strategic focus, and rebuilding stakeholder confidence during his interim tenure. Leadership will prioritize scaling clinical adoption of AVITA’s acute wound care platform and translating momentum into consistent performance.
AVITA Medical (NASDAQ: RCEL) announced that RECELL GO received Australia TGA certification and New Zealand WAND listing, enabling commercialization for burn and acute wound treatment in both markets. Revolution Surgical, the exclusive distributor, expects to begin commercial launch within weeks. The system automates and standardizes RECELL Spray-On Skin preparation, which the company says reduces manual steps and clinical burden.
AVITA Medical (NASDAQ: RCEL) will report its first quarter 2026 financial results after U.S. market close on Thursday, May 14, 2026. A conference call and webcast will be held at 1:30 p.m. PT (May 15, 2026, 6:30 a.m. AEST) to discuss results and business highlights. Replay will be available on the company's investor relations Events page.
AVITA Medical (NASDAQ: RCEL) announced that founder Professor Fiona Wood received the American Burn Association Lifetime Achievement Award on April 15, 2026.
The award recognizes her pioneering development of spray-on skin technology commercialized as RECELL, more than 30 years of leadership in burn care, and global influence on clinical practice.
AVITA Medical (NASDAQ: RCEL) reported positive interim Cohealyx-I results showing a mean time to skin graft of 13.6 days versus a 33.2-day literature benchmark (~20-day reduction) with statistical superiority (p<0.001).
The 40-patient interim analysis showed a median time to graft of 11 days, grafting as early as 5 days, 72% grafted within 14 days, and 90% investigator satisfaction; full dataset expected in 2026.
AVITA Medical (NASDAQ: RCEL) secured a 10-year agreement with BARDA under Project BioShield, valued at up to $25.5 million to strengthen U.S. burn mass casualty preparedness. The contract provides BARDA access to 3,000 RECELL units over the term, plus procurement options and readiness support.
Approximately $3.97 million is expected as access-maintenance and readiness fee revenue over 10 years; remaining value reflects optional procurements BARDA may exercise.
AVITA Medical (NASDAQ: RCEL) will present new clinical and case data at the American Burn Association (ABA) 2026 meeting on April 7, 2026, including an interim analysis from the ongoing Cohealyx‑I multi‑center study and investigator‑led real‑world RECELL and PermeaDerm findings. The company will feature 19 presentations and 3 company‑sponsored events, highlighting potential reductions in hospital length of stay and resource use.
The exhibit theme is Healing at the Speed of Life™, emphasizing recovery outcomes beyond wound closure.
AVITA Medical (NASDAQ: RCEL) said interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 at 8:10 a.m. PT / 11:10 a.m. ET.
A live and archived webcast will be available via the company’s Events & Presentations page at its investor website.